OBJECTIVE: Assess the cost-effectiveness of a 16-week weight loss intervention (Weight-Wise) for low-income midlife women. METHOD: A randomized controlled trial conducted in North Carolina in 2007 tested a weight loss intervention among 143 women (40-64 years old, mean BMI=35.1 kg/m(2)). Women were randomized to one of two arms-special intervention (n=72) and a wait-listed control group (n=71). Effectiveness measures included changes in weight, systolic and diastolic blood pressure, total cholesterol, and HDL cholesterol. Cost-effectiveness measures calculated life years gained (LYG) from changes in weight, based on excess years life lost (YLL) algorithm. RESULTS: Intervention participants had statistically significant decreases in weight (kg) (-4.4 95% CI=-5.6, -3.2) and in systolic blood pressure (-6.2 mm Hg, 95% CI=-10.6, -1.7) compared to controls. Total cost of conducting Weight-Wise was $17,403, and the cost per participant in intervention group was $242. The incremental cost per life year gained (discounted) from a decrease in obesity was $1862. CONCLUSION: Our results suggest the Weight-Wise intervention may be a cost-effective approach to improving the health of low-income women.
Cost-effectiveness of a behavioral weight loss intervention for low-income women
The Weight-Wise Program
Gustafson, A., Khavjou, O., Stearns, SC., Keyserling, TC., Gizlice, Z., Lindsley, S., Bramble, K., Garcia, B., Johnston, L., Will, J., Poindexter, P., Ammerman, AS., & Samuel-Hodge, CD. (2009). Cost-effectiveness of a behavioral weight loss intervention for low-income women: The Weight-Wise Program. Preventive Medicine, 49(5), 390-395. https://doi.org/10.1016/j.ypmed.2009.09.007
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Epigenetic biomarkers for smoking cessation
A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood